Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
O. Oliveira, M. Villar, R. Duarte (Porto, Lisbon, Vila Nova de Gaia, Portugal). Predictors of treatment outcome in multidrug-resistant tuberculosis. Eur Respir J 2011; 38: Suppl. 55, 3296

Member's Comments

No comment yet.

Related content which might interest you: Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal Source: Eur Respir J 2013; 42: 1747-1749 Year: 2013 Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Effect of fluoroquinolones on microbiologic outcome and survival in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 380s Year: 2006 Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis Source: Eur Respir J 2013; 41: 1393-1400 Year: 2013 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Recurrence after successful treatment among patients with multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016 Year: 2017 Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019 Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid Source: Eur Respir J 2015; 45: 1498-1501 Year: 2015 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004 Long-term results of multidrug-resistant tuberculosis treatment. Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB Source: Breathe 2008; 6: 161 Year: 2009 Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001 Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021 Outcome of pulmonary multidrug-resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 419s Year: 2007 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018